Comment on “In Silico Comparison of Separate or Combinatorial Effects of Potential Inhibitors of the SARS-CoV-2 Binding Site of ACE2”
Abstract
No Abstract
1. Shakhsi-Niaei, M., Soureshjani, E. H., Babaheydari, A. K. (2021). In Silico Comparison of Separate or Combinatorial Effects of Potential Inhibitors of the SARS-CoV-2 Binding Site of ACE2. Iranian journal of public health, 50(5):1028–1036.
2 Fakhrae Z, Bitaraf S, Nashibi R, et al (2021). Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on the Clinical Outcome in COVID-19 Patients with Hypertension. J Cell Mol Anesth, 6(4):323-8.
3. Baral, R., Tsampasian, V., Debski, M., et al (2021). Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients with COVID-19: A Systematic Review and Meta-analysis. JAMA network open, 4(3), e213594.
4. Xie, Q., Tang, S., Li, Y. (2021). The divergent protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on clinical outcomes of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Annals of palliative medicine, apm-21-972.
5. Abubakar, M. B., Usman, D., El-Saber Batiha, G. et al (2021). Natural Products Modulating Angiotensin Converting Enzyme 2 (ACE2) as Potential COVID-19 Therapies. Frontiers in pharmacology, 12, 629935.
6. Heidary F, Varnaseri M, Gharebaghi R. (2020). The Potential Use of Persian Herbal Medicines Against COVID-19 Through Angiotensin-Converting Enzyme 2. Arch Clin Infect Dis.15(COVID-19):e102838.
7. Bahramsoltani R, Rahimi R. (2020). An Evaluation of Traditional Persian Medicine for the Management of SARS-CoV-2. Front Pharmacol, 11:571434.
8. Villena-Tejada, M., Vera-Ferchau, I., Cardona-Rivero, A., et al (2021). Use of medicinal plants for COVID-19 prevention and respiratory symptom treatment during the pandemic in Cusco, Peru: A cross-sectional survey. PloS one, 16(9), e0257165.
9. Shekhar R, Garg I, Pal S, Kottewar S, Sheikh AB. (2021). COVID-19 Vaccine Booster: To Boost or Not to Boost. Infect Dis Rep, 13(4):924-929.
10. Samui P, Mondal J, Khajanchi S. (2020). A mathematical model for COVID-19 transmission dynamics with a case study of India. Chaos Solitons Fractals, 140:110173.
2 Fakhrae Z, Bitaraf S, Nashibi R, et al (2021). Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on the Clinical Outcome in COVID-19 Patients with Hypertension. J Cell Mol Anesth, 6(4):323-8.
3. Baral, R., Tsampasian, V., Debski, M., et al (2021). Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients with COVID-19: A Systematic Review and Meta-analysis. JAMA network open, 4(3), e213594.
4. Xie, Q., Tang, S., Li, Y. (2021). The divergent protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on clinical outcomes of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Annals of palliative medicine, apm-21-972.
5. Abubakar, M. B., Usman, D., El-Saber Batiha, G. et al (2021). Natural Products Modulating Angiotensin Converting Enzyme 2 (ACE2) as Potential COVID-19 Therapies. Frontiers in pharmacology, 12, 629935.
6. Heidary F, Varnaseri M, Gharebaghi R. (2020). The Potential Use of Persian Herbal Medicines Against COVID-19 Through Angiotensin-Converting Enzyme 2. Arch Clin Infect Dis.15(COVID-19):e102838.
7. Bahramsoltani R, Rahimi R. (2020). An Evaluation of Traditional Persian Medicine for the Management of SARS-CoV-2. Front Pharmacol, 11:571434.
8. Villena-Tejada, M., Vera-Ferchau, I., Cardona-Rivero, A., et al (2021). Use of medicinal plants for COVID-19 prevention and respiratory symptom treatment during the pandemic in Cusco, Peru: A cross-sectional survey. PloS one, 16(9), e0257165.
9. Shekhar R, Garg I, Pal S, Kottewar S, Sheikh AB. (2021). COVID-19 Vaccine Booster: To Boost or Not to Boost. Infect Dis Rep, 13(4):924-929.
10. Samui P, Mondal J, Khajanchi S. (2020). A mathematical model for COVID-19 transmission dynamics with a case study of India. Chaos Solitons Fractals, 140:110173.
| Files | ||
| Issue | Vol 51 No 5 (2022) | |
| Section | Letter to the Editor | |
| DOI | https://doi.org/10.18502/ijph.v51i5.9443 | |
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Gharebaghi R, Heidary F. Comment on “In Silico Comparison of Separate or Combinatorial Effects of Potential Inhibitors of the SARS-CoV-2 Binding Site of ACE2”. Iran J Public Health. 2022;51(5):1198-1199.
